Cysteine-cysteine chemokine ligand 5 (CCL5) is known to play an important role with immunoregulatory and inflammatory activities in the formation of granuloma during infection with Mycobacterium tuberculosis. About 90 subjects, involving 50 patients with pulmonary TB and 40 apparently healthy individuals (as a control group) were collected from primary health care center\AL-Sadur city sector/ Baghdad City/ Iraq, and at specialized chest and respiratory diseases center in Wassit City /Iraq during the period from January 2019 to May 2019. The study was carried out to investigate serum level of CCL-5 of both patients and control by using enzyme linked immunosorbent assay (ELISA), and to determine the association between CCL5 genotypes with pulmonary tuberculosis susceptibility in Iraqi population. Genotyping analysis of CCL5 rs2107538 was performed by using amplification refractory mutation system (ARMS-PCR) method. The results revealed that serum levels of CCL-5 was significantly, (P ≤0.01) increased in pulmonary tuberculosis patients compared to control. The mean ±SE of CCL-5 level in PTB patients and controls were 455.40 ±25.35 ng/L and 80.86 ± 5.96 ng/L, respectively. Analysis of H-W equilibrium revealed that CCL-5 rs2107538 GG, GA and AA genotypes in TB patient group were not in agreement with the equilibrium and there was a significant variation (p ≤ 0.05) between the observed and expected frequencies. While control group showed an agreement with the equilibrium. At position rs2107538, CCL-5 GG genotype showed a significant increased level of CCL-5 (531.01 ± 23.03 ng/L) in PTB patients compared to GA genotype (305.28 ± 33.45 ng/L) and AA genotype (150.27 ± 11.60 ng/L) of the patients. This study suggest that CCL-5 could be considered as a good biomarker for diagnosis of PTB, while it exclude the CCL-5 rs2107538 as major risk factor for tuberculosis in the Iraqi population